Subcutaneous versus Sublingual Allergen Immunotherapy in Allergic Rhinitis and Asthma: A Comparative Narrative Review
DOI:
https://doi.org/10.12775/QS.2026.51.68476Keywords
Allergen immunotherapy, subcutaneous immunotherapy, sublingual immunotherapy, allergic rhinitis, allergic asthma, efficacy, safetyAbstract
Allergen-specific immunotherapy (AIT) represents the only disease-modifying intervention for IgE-mediated allergic diseases, including allergic rhinitis and allergic asthma. Among the currently available administration routes, subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT) are the most extensively studied and clinically implemented. Despite their widespread use, uncertainty persists regarding their relative efficacy, safety, and real-world applicability across different patient populations and allergen types.
AIM: The aim of this study was to critically compare the clinical effectiveness, safety profile, and treatment adherence of SCIT and SLIT based on data derived from PubMed-indexed randomized controlled trials, systematic reviews, and meta-analyses.
Material and methods: A narrative synthesis of peer-reviewed literature was conducted, focusing on studies directly or indirectly comparing SCIT and SLIT in patients with allergic rhinitis, allergic asthma, or rhinoconjunctivitis. Primary endpoints included symptom score reduction and medication use, while secondary outcomes encompassed adverse events, immunological responses, and adherence rates.
Results: Both SCIT and SLIT demonstrated significant clinical efficacy compared with placebo or pharmacotherapy alone. Overall symptom reduction and medication sparing effects were largely comparable between the two modalities. SCIT showed a trend toward slightly greater efficacy in selected allergens, particularly grass pollen, whereas SLIT consistently exhibited a superior safety profile with fewer systemic adverse reactions.
Conclusion: SCIT and SLIT are both effective forms of allergen immunotherapy. While SCIT may provide marginal advantages in symptom control in specific clinical contexts, SLIT offers improved safety and convenience. Treatment choice should therefore be individualized, considering patient characteristics, allergen profile, and risk tolerance.
References
1. Calderón, M. A., Alves, B., Jacobson, M., Hurwitz, B., Sheikh, A., & Durham, S. R. (2007). Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database of Systematic Reviews, (1), CD001936. https://doi.org/10.1002/14651858.CD001936.pub2
2. Bousquet, J., Van Cauwenberge, P., & Khaltaev, N. (2001). Allergic rhinitis and its impact on asthma (ARIA). Journal of Allergy and Clinical Immunology, 108(5 Suppl), S147–S334. https://doi.org/10.1067/mai.2001.118891
3. Akdis, C. A., & Akdis, M. (2011). Mechanisms of allergen-specific immunotherapy. Journal of Allergy and Clinical Immunology, 127(1), 18–27. https://doi.org/10.1016/j.jaci.2010.11.030
4. Larche, M., Akdis, C. A., & Valenta, R. (2006). Immunological mechanisms of allergen-specific immunotherapy. Nature Reviews Immunology, 6(10), 761–771. https://doi.org/10.1038/nri1934
5. Durham, S. R., Walker, S. M., Varga, E. M., et al. (1999). Long-term clinical efficacy of grass-pollen immunotherapy. New England Journal of Medicine, 341(7), 468–475. https://doi.org/10.1056/NEJM199908123410702
6. Cox, L., Nelson, H., Lockey, R., et al. (2011). Allergen immunotherapy: A practice parameter third update. Journal of Allergy and Clinical Immunology, 127(1 Suppl), S1–S55. https://doi.org/10.1016/j.jaci.2010.09.034
7. Lockey, R. F., Nicoara-Kasti, G. L., Theodoropoulos, D. S., & Bukantz, S. C. (2001). Systemic reactions and fatalities associated with allergen immunotherapy. Annals of Allergy, Asthma & Immunology, 87(1), 47–55. https://doi.org/10.1016/S1081-1206(10)62286-1
8. Canonica, G. W., Cox, L., Pawankar, R., et al. (2014). Sublingual immunotherapy: World Allergy Organization position paper. World Allergy Organization Journal, 7(1), 6. https://doi.org/10.1186/1939-4551-7-6
9. Passalacqua, G., & Durham, S. R. (2007). Allergen immunotherapy in allergic rhinitis. Clinical & Experimental Allergy, 37(1), 25–33. https://doi.org/10.1111/j.1365-2222.2006.02633.x
10. Kim, J. M., Lin, S. Y., Suarez-Cuervo, C., et al. (2013). Allergen-specific immunotherapy for pediatric asthma and rhinoconjunctivitis. Pediatrics, 131(6), 1155–1167. https://doi.org/10.1542/peds.2013-0359
11. Radulovic, S., Calderón, M. A., Wilson, D., & Durham, S. R. (2010). Sublingual immunotherapy for allergic rhinitis. Cochrane Database of Systematic Reviews, (12), CD002893. https://doi.org/10.1002/14651858.CD002893.pub2
12. Di Bona, D., Plaia, A., Leto-Barone, M. S., et al. (2012). Efficacy of subcutaneous and sublingual immunotherapy with grass allergens. Journal of Allergy and Clinical Immunology, 130(5), 1097–1107. https://doi.org/10.1016/j.jaci.2012.08.023
13. Nelson, H. S. (2014). Subcutaneous immunotherapy versus sublingual immunotherapy. Journal of Allergy and Clinical Immunology, 133(3), 846–847. https://doi.org/10.1016/j.jaci.2013.12.1046
14. Huang, Y., Wang, C., Cao, F., et al. (2019). Comparison of subcutaneous and sublingual immunotherapy in children. Allergy, 74(11), 2246–2256. https://doi.org/10.1111/all.13895
15. Abramson, M. J., Puy, R. M., & Weiner, J. M. (2010). Injection allergen immunotherapy for asthma. Cochrane Database of Systematic Reviews, (8), CD001186. https://doi.org/10.1002/14651858.CD001186.pub2
16. Virchow, J. C., Backer, V., Kuna, P., et al. (2016). Efficacy of sublingual house dust mite immunotherapy in asthma. Journal of Allergy and Clinical Immunology, 138(6), 1631–1638. https://doi.org/10.1016/j.jaci.2016.04.046
17. Passalacqua, G., Compalati, E., Schiappoli, M., & Senna, G. (2009). Safety of sublingual immunotherapy. Clinical & Experimental Allergy, 39(7), 1039–1046. https://doi.org/10.1111/j.1365-2222.2009.03244.x
18. Epstein, T. G., Liss, G. M., Murphy-Berendts, K., & Bernstein, D. I. (2014). Risk factors for fatal reactions to allergen immunotherapy. Annals of Allergy, Asthma & Immunology, 113(6), 630–634. https://doi.org/10.1016/j.anai.2014.09.002
19. Senna, G., Lombardi, C., Canonica, G. W., & Passalacqua, G. (2010). How adherent are patients to sublingual immunotherapy? Allergy, 65(11), 1445–1448. https://doi.org/10.1111/j.1398-9995.2010.02386.x
20. Kiel, M. A., Röder, E., Gerth van Wijk, R., Al, M. J., & Hop, W. C. (2013). Real-life compliance and persistence among allergen immunotherapy users. Journal of Allergy and Clinical Immunology, 132(2), 353–360. https://doi.org/10.1016/j.jaci.2013.02.026
21. Bousquet, J., et al. (2016). ARIA 2016: Care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle. Clinical and Translational Allergy, 6, 47. https://doi.org/10.1186/s13601-016-0137-4
22. Incorvaia, C., Mauro, M., Leo, G., & Ridolo, E. (2016). Adherence to sublingual immunotherapy. Current Allergy and Asthma Reports, 16(2), 12. https://doi.org/10.1007/s11882-015-0586-1
23. Egert-Schmidt, A. M., et al. (2014). Patient adherence to SLIT. Allergy, 69(6), 700–708. https://doi.org/10.1111/all.12382
24. Shamji, M. H., & Durham, S. R. (2017). Mechanisms of allergen immunotherapy. Clinical & Experimental Allergy, 47(10), 1235–1244. https://doi.org/10.1111/cea.12978
25. Bousquet, J., et al. (2019). 2019 ARIA Care pathways for allergen immunotherapy. Allergy, 74(11), 2087–2102. https://doi.org/10.1111/all.13805
26. Hankin, C. S., et al. (2013). Economic evaluation of allergen immunotherapy. Annals of Allergy, Asthma & Immunology, 111(6), 458–464. https://doi.org/10.1016/j.anai.2013.09.014
27. Reinhold, T., & Brüggenjürgen, B. (2017). Cost-effectiveness of grass pollen subcutaneous immunotherapy compared with sublingual immunotherapy and symptomatic treatment. Allergo Journal International, 26(1), 7–15. https://doi.org/10.1007/s40629-016-0002-y
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Tomasz Pietrucha, Mikołaj Gołdyn, Karolina Kubala, Magdalena Grabińska, Paulina Halik, Justyna Jusiak
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 4
Number of citations: 0
